1、SABCS2015 早期乳腺癌年度回顾Early breast cancer-More or Less?,仅供医疗专业人士参考审批号/有效期至：,ER阳性乳腺癌-“更少”的治疗,至今我们知晓哪些？ 化疗对部分ER阳性的乳腺癌 并非是必须的（TAILORx，S1-08*）我们是否清楚哪些患者需要延长辅助治疗？是否所有患者都需要延长辅助治疗？（ASCO BCI）哪些患者需要“更多”的治疗？ （S2-02*: The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal pat
2、ients of the ABCSG-18 trial）,*High risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: Results from DBCG77B randomized trial*The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial,Trial
3、 Assigning Individualized Options for Treatment (TAILORx),入组标准：淋巴结阴性ER+, HER2-T1c-T2（high risk T1b）18-75岁无部分乳房照射（PBI）计划,统计学设计：RS11-25：非劣效90% vs 87% Idfs835个DFS事件RS2cm,许多ER阳性乳腺癌并不受益于化疗TAILORx研究定义的低危患者Luminal A型乳腺癌我们是否清楚哪些患者需要延长辅助治疗？BCI能够鉴别出哪些患者可以在5年终止治疗骨相关的治疗药物能够改善骨密度，并且改善预后,ER阳性乳腺癌的分子分型,HER2阳性乳腺癌,我们
4、是否可以对部分患者给予“更少”的治疗？ 小肿瘤（S6-06*）三阳性乳腺癌（S5-03*，ASCO）哪些患者需要“更多”的辅助抗HER2治疗？延长抗HER2治疗（S5-02*）,*The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?* Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety
5、, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer* Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from
6、 a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET),一期HER2阳性乳腺癌的治疗,一期HER2阳性乳腺癌的治疗,一期HER2阳性乳腺癌：总生存期,一期HER2阳性乳腺癌：不同分型分析,APT研究：12周紫杉醇联合曲妥珠单抗,Rinawi CCR 2013,ADAPT HER2+/HR+：试验设计,预后,活检,疗效,活检,三周治疗,内分泌治疗,曲妥珠单抗,内分泌治疗,手术*,终点,*推荐术后标准化疗，完成共1年的曲妥珠单抗治疗,Presented By Nadia Harbeck at 2015 ASCO
7、 Annual Meeting,ADAPT HER2+/HR+：pCR（乳腺和淋巴结非浸润性癌）,ADAPT HER2+/HR+：早期反应的生物标记物,早期反应： 低肿瘤细胞密度（500 肿瘤细胞）或者三周内Ki67 下降30%,Carey et al Proc ASCO 2014,HER2阳性，HR阴性乳腺癌的固有亚型,ExteNET：最终研究设计,HER2+乳腺癌(局部)既往辅助曲妥珠单抗&化疗淋巴结阳性或新辅助治疗后残留浸润性疾病ER/PR阳性或阴性,1:1随机分组,来那替尼1年240mg/天,安慰剂1年,N=2840,2年随访的DFS,5年随访的DFS,5年以上生存,A,B,C,主要终
8、点：无浸润性疾病生存期(iDFS)iDFS：HR=0.67 (0.50-0.91); p=0.009激素受体阳性 (n=1631; 57.4%); HR=0.51; p=0.001中心确认的HER2阳性60% (n=1463; 51%); HR=0.51; p=0.002,Presented By Arlene Chan at 2015 ASCO Annual Meeting,3年iDFS分析（ITT=2840）,无疾病生存率(%),来那替尼 安慰剂,安慰剂,来那替尼,双侧检验 P=0.023HR(95%CI)=0.74(0.56-0.96),不同激素受体状态: 3年iDFS,HR阳性,HR阴
9、性,3年iDFS分析：激素受体状态&中心确认的HER2阳性,HER2阳性乳腺癌,我们是否可以对部分患者给予“更少”的治疗？ 小肿瘤-NCCN指南给予确认三阳性乳腺癌-显示这类患者需要一些新化疗方案哪些患者需要“更多”的辅助抗HER2治疗？激素受体阳性乳腺癌？,哪些患者需要“更多”的治疗？增加卡铂（S2-04*，S2-05*, S6-07*）新辅助化疗后-需要新的方案（S1-07#）是否有些患者需要“更少”的治疗？肿瘤浸润淋巴细胞（TILs）（S1-03&）雄激素受体表达,三阴性乳腺癌,*Early survival analysis of the randomized phase II tri
10、al investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)* Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: O
11、utcomes from CALGB 40603 (Alliance)* Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial# A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative patholo
12、gic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)& Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy,不同亚型的针对性靶向治疗,卡铂提高TNBC的pCR率,Von Minckwitz et al.
13、Lancet Onco 2014,增加卡铂能够改善TNBC的DFS,研究活检冰冻和固定,C40603：方案-随机二期研究,临床分期为-期三阴性乳腺癌,22R,紫杉醇 80mg/m2，每周1次12周,贝伐单抗 10mg/kg 每周2次9周,主要终点：乳房pCR（*ASCO 2013),ddAC4,紫杉醇 80mg/m2，每周1次12周,卡铂 AUC 6 每周3次4周,紫杉醇 80mg/m2，每周1次12周,卡铂 AUC 6 每周3次4周,紫杉醇 80mg/m2，每周1次12周,贝伐单抗 10mg/kg 每周2次9周,ddAC4,ddAC4,ddAC4,手术XRT未计划行辅助全身治疗,Presen
14、ted By Mehra Golshan at 2015 ASCO Annual Meeting,OR=1.71 p=0.0029,CALGB40603：乳腺/腋窝pCR（ypT0/isN0）,OR=1.36 p=0.0570,CALGB40603：乳腺/腋窝pCR患者EFS,CALGB40603：是否增加卡铂的EFS,术后推荐标准化疗（4 EC）/ 12周后活检（non-pCR）,ADAPT HR-/HER2-：研究设计,ADAPT HR-/HER2-：病理完全缓解（pCR）,分子分型变化不影响卡铂治疗获益（交互检验 p=0.93）,卡铂：分子分型和pCR的相关性,乳腺pCR：,根据gBRC
15、A状态和卡铂治疗TNBC的pCR率,新辅助治疗后有残余病灶：CREATE -X研究设计,日韩进行的前瞻性、多中心、开放、随机III期研究,分层因素：ER，年龄，NAC，ypN，5FU等标准治疗：HR+：后续内分泌治疗HR-：没有后续系统治疗,CREATE X：DFS和OS,CREATE X：亚组分析,DDFS和OS分析结果,DDFS,OS,基质TILs 20%的淋巴结阴性TNBC患者：有较好的D-DFS,TNBC不同亚型与化疗反应的相关性（蒽环-紫杉药）,Masuda et al Clin Cancer Res 2013,基于AR和pCR的TNCB的5年DFS,DFS-month,哪些患者需要
16、“更多”的治疗？增加卡铂-仍悬而未决新辅助化疗后-需要新的方案是否有些患者需要“更少”的治疗？肿瘤浸润淋巴细胞（TILs）雄激素受体表达,三阴性乳腺癌,55,Author | 00 Month Year,Set area descriptor | Sub level 1,Confidentiality Notice,This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and
17、remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 2 Kingdom Street, London, W2 6BD, UK, T: +44(0)20 7604 8000, F: +44 (0)20 7604 8151, ,
